ICVX Live signals | Maximize Profits with Getagraph.com

BUY 104454 min ago

@ $15.42

Issued: 13 Feb 2024 @ 15:51

Return: -0.71%

Previous signal: Feb 13 - 13:32

Previous signal: Sell

Return: -0.39 %

Live Chart Being Loaded With Signals

Commentary (16 Feb 2024 @ 16:00):

Stats
Today's Volume	8.56M
Average Volume	1.05M
Market Cap	769.04M
EPS	$0 ( 2024-04-04 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-6.96
ATR14	$0.208 (1.36%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-19	Ra Capital Management, L.p.	Sell	638 668	Common Stock
2024-02-19	Ra Capital Management, L.p.	Sell	22 278	Stock Option (Right to Buy)
2024-02-19	Ra Capital Management, L.p.	Sell	17 000	Stock Option (Right to Buy)
2024-02-19	Simpson Adam K.	Sell	129 032	Common Stock
2024-02-19	Simpson Adam K.	Sell	191 449	Stock Option (Right to Buy)

INSIDER POWER
-94.08
Last 100 transactions
Buy: 419 662 \| Sell: 10 978 493

Volume Correlation

Long: 0.31 (neutral)

Short: 0.00 (neutral)

Signal:(55.408) Neutral

Icosavax, Inc. Correlation

10 Most Positive Correlations
TOUR	0.936
TELA	0.931
MOMO	0.927
REPL	0.927
QTT	0.925
FGEN	0.924
VBNK	0.922
GGAL	0.922
FCBP	0.921
NIU	0.919

10 Most Negative Correlations
THTX	-0.904
GOSS	-0.899
PCRX	-0.895
USCB	-0.894
LARK	-0.891
ENPH	-0.878
SHSP	-0.877
SWAV	-0.875
XFOR	-0.87
NETE	-0.87

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Icosavax, Inc. Correlation - Currency/Commodity

0.84
( strong )

0.75
( moderate )

-0.84
( strong negative )

0.84
( strong )

-0.04
( neutral )

-0.57
( weak negative )

Icosavax, Inc. Financials

Annual	2022
Revenue:	$582 000
Gross Profit:	$-1.26M (-216.67 %)
EPS:	$-2.23

FY	2022
Revenue:	$582 000
Gross Profit:	$-1.26M (-216.67 %)
EPS:	$-2.23

FY	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$0

FY	2020
Revenue:	$1.62M
Gross Profit:	$0.00 (0.00 %)
EPS:	$-1.820

Financial Reports:

No articles found.

Icosavax, Inc.

Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases. The company, with the help of its virus-like particle (VLP) platform technology, focuses primarily on life-threatening respiratory diseases. Its products in pipeline include IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; IVX-A12, a respiratory syncytial virus (RSV) monovalent antigen candidate with RSV/human metapneumovirus (hMPV) bivalent target indication; IVX-241, a vaccine candidate with hMPV target; and IVX-411, an original receptor binding domain (RBD) sequence antigen with SARS-CoV-2 target indication and is under Phase 1/2 clinical trial. The company was incorporated in 2017 and is headquartered in Seattle, Washington.